168 related articles for article (PubMed ID: 9806525)
1. Synthetic, implantable polymers for local delivery of IUdR to experimental human malignant glioma.
Williams JA; Yuan X; Dillehay LE; Shastri VR; Brem H; Williams JR
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):631-9. PubMed ID: 9806525
[TBL] [Abstract][Full Text] [Related]
2. Synthetic, implantable polymers for IUdR radiosensitization of experimental human malignant glioma.
Yuan X; Dillehay LE; Williams JR; Williams JA
Cancer Biother Radiopharm; 1999 Jun; 14(3):187-202. PubMed ID: 10850303
[TBL] [Abstract][Full Text] [Related]
3. Implantable biodegradable polymers for IUdR radiosensitization of experimental human malignant glioma.
Williams JA; Dillehay LE; Tabassi K; Sipos E; Fahlman C; Brem H
J Neurooncol; 1997 May; 32(3):181-92. PubMed ID: 9049879
[TBL] [Abstract][Full Text] [Related]
4. IUdR polymers for combined continuous low-dose rate and high-dose rate sensitization of experimental human malignant gliomas.
Yuan X; Dillehay LE; Williams JR; Shastri VR; Williams JA
Int J Cancer; 2001 Apr; 96(2):118-25. PubMed ID: 11291095
[TBL] [Abstract][Full Text] [Related]
5. Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma.
Yuan X; Tabassi K; Williams JA
Radiat Oncol Investig; 1999; 7(4):218-30. PubMed ID: 10492162
[TBL] [Abstract][Full Text] [Related]
6. Synthetic, implantable, biodegradable polymers for controlled release of radiosensitizers.
Yuan X; Fahlman C; Tabassi K; Williams JA
Cancer Biother Radiopharm; 1999 Jun; 14(3):177-86. PubMed ID: 10850302
[TBL] [Abstract][Full Text] [Related]
7. Iodo-2'-deoxyuridine (IUdR) and 125IUdR loaded biodegradable microspheres for controlled delivery to the brain.
Reza MS; Whateley TL
J Microencapsul; 1998; 15(6):789-801. PubMed ID: 9818956
[TBL] [Abstract][Full Text] [Related]
8. Preclinical toxicity and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine radiosensitization in U251 human glioblastoma xenografts.
Kinsella TJ; Vielhuber KA; Kunugi KA; Schupp J; Davis TW; Sands H
Clin Cancer Res; 2000 Apr; 6(4):1468-75. PubMed ID: 10778979
[TBL] [Abstract][Full Text] [Related]
9. Schedule-dependent drug effects of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as an in vivo radiosensitizer in U251 human glioblastoma xenografts.
Seo Y; Yan T; Schupp JE; Radivoyevitch T; Kinsella TJ
Clin Cancer Res; 2005 Oct; 11(20):7499-507. PubMed ID: 16243824
[TBL] [Abstract][Full Text] [Related]
10. Interstitial delivery of carboplatin via biodegradable polymers is effective against experimental glioma in the rat.
Olivi A; Ewend MG; Utsuki T; Tyler B; Domb AJ; Brat DJ; Brem H
Cancer Chemother Pharmacol; 1996; 39(1-2):90-6. PubMed ID: 8995504
[TBL] [Abstract][Full Text] [Related]
11. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain.
Brem H; Tamargo RJ; Olivi A; Pinn M; Weingart JD; Wharam M; Epstein JI
J Neurosurg; 1994 Feb; 80(2):283-90. PubMed ID: 8283268
[TBL] [Abstract][Full Text] [Related]
12. Enhancement radiation-induced apoptosis in C6 glioma tumor-bearing rats via pH-responsive magnetic graphene oxide nanocarrier.
Shirvalilou S; Khoei S; Khoee S; Mahdavi SR; Raoufi NJ; Motevalian M; Karimi MY
J Photochem Photobiol B; 2020 Apr; 205():111827. PubMed ID: 32120183
[TBL] [Abstract][Full Text] [Related]
13. Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma.
Frazier JL; Wang PP; Case D; Tyler BM; Pradilla G; Weingart JD; Brem H
J Neurooncol; 2003 Sep; 64(3):203-9. PubMed ID: 14558595
[TBL] [Abstract][Full Text] [Related]
14. Continuous delivery of endogenous inhibitors from poly(lactic-co-glycolic acid) polymeric microspheres inhibits glioma tumor growth.
Benny O; Duvshani-Eshet M; Cargioli T; Bello L; Bikfalvi A; Carroll RS; Machluf M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):768-76. PubMed ID: 15701867
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas.
Judy KD; Olivi A; Buahin KG; Domb A; Epstein JI; Colvin OM; Brem H
J Neurosurg; 1995 Mar; 82(3):481-6. PubMed ID: 7861228
[TBL] [Abstract][Full Text] [Related]
16. Development of a magnetic nano-graphene oxide carrier for improved glioma-targeted drug delivery and imaging: In vitro and in vivo evaluations.
Shirvalilou S; Khoei S; Khoee S; Raoufi NJ; Karimi MR; Shakeri-Zadeh A
Chem Biol Interact; 2018 Nov; 295():97-108. PubMed ID: 30170108
[TBL] [Abstract][Full Text] [Related]
17. Protracted exposure radiosensitization of experimental human malignant glioma.
Williams JA; Williams JR; Yuan X; Dillehay LE
Radiat Oncol Investig; 1998; 6(6):255-63. PubMed ID: 9885941
[TBL] [Abstract][Full Text] [Related]
18. Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model.
Mairs RJ; Wideman CL; Angerson WJ; Whateley TL; Reza MS; Reeves JR; Robertson LM; Neshasteh-Riz A; Rampling R; Owens J; Allan D; Graham DI
Br J Cancer; 2000 Jan; 82(1):74-80. PubMed ID: 10638969
[TBL] [Abstract][Full Text] [Related]
19. Local intracerebral delivery of endogenous inhibitors by osmotic minipumps effectively suppresses glioma growth in vivo.
Giussani C; Carrabba G; Pluderi M; Lucini V; Pannacci M; Caronzolo D; Costa F; Minotti M; Tomei G; Villani R; Carroll RS; Bikfalvi A; Bello L
Cancer Res; 2003 May; 63(10):2499-505. PubMed ID: 12750272
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model.
Wang W; Cho HY; Rosenstein-Sisson R; Marín Ramos NI; Price R; Hurth K; Schönthal AH; Hofman FM; Chen TC
J Neurosurg; 2018 Mar; 128(3):695-700. PubMed ID: 28409734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
